A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

NCT01027169 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: safinamide
DRUG: safinamide
DRUG: safinamide

Sponsor

Newron Pharmaceuticals SPA